Acrivon Therapeutics

Historical price data

Acrivon Therapeutics is a precision oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted therapies matched to patients via predictive OncoSignature tests. Its strategy centers on in-licensing and internally developing small molecule inhibitors, with a lead Phase 2 asset, ACR-368, and a dual-inhibitor clinical candidate, ACR-2316. The company aims to improve therapeutic outcomes by directly profiling the functional protein drivers of cancer, a paradigm shift from traditional genomics.

The Acrivon Predictive Precision Proteomics (AP3) platform uses mass spectrometry-based phosphoproteomics to discover predictive biomarkers and translates them into automated, quantitative OncoSignature companion diagnostic tests for patient selection.